Dr. Reddy's Laboratories SA
By therapeutic area
| Therapeutic area | Premium | Deals |
|---|---|---|
| oncology | ×0.70 | 3 |
By stage at signing
Not enough phase-specific data (need ≥3 deals per phase).
Strategy profile
Based on 13 disclosed transactions, Dr. Reddy's Laboratories SA concentrates its licensing activity in Oncology, Neurology, and Other. Dr. Reddy's Laboratories SA pays a 0.70x discount to market median, with the strongest premiums in Oncology (0.70x). Their most common deal structure is License, with an average disclosed value of $389M. Most recent activity: 2026.
Premium by therapeutic area
How Dr. Reddy's Laboratories SA pays relative to peer medians in each TA
Pipeline coverage & gaps
Dr. Reddy's Laboratories SA has disclosed activity in 1 of 12 tracked therapeutic areas. Gaps may represent whitespace opportunities for licensors.
Deal type breakdown
How this buyer structures its transactions
| Deal type | Count | Avg upfront | Avg total value |
|---|---|---|---|
| LicensePrimary | 13 | $12M | $389M |
Recent disclosed deals
| Year | Asset | Licensor | Indication | Phase | Upfront | Total |
|---|---|---|---|---|---|---|
| 2026 | eftilagimod alfa | Immutep Limited | nsclc | phase_3 | $20M | $370M |
| 2025 | eftilagimod alfa | Immutep | nsclc | phase_3 | $20M | $370M |
| 2025 | Eftilagimod Alfa | Immutep Limited | nsclc | phase_3 | $20M | $370M |
| 2025 | REZLIDHIA | Rigel Pharmaceuticals, Inc. | mIDH1 acute myeloid leukemia | approved | $4M | $40M |
| 2025 | HLX15 | Shanghai Henlius Biotech, Inc. | multiple myeloma | phase_1 | $33M | $132M |
| 2025 | REZLIDHIA | Rigel Pharmaceuticals | aml | approved | $4M | $40M |
| 2024 | COYA 302 | Coya Therapeutics | ALS | phase_1 | $400,000 | $23M |
| 2024 | AVT03 | Alvotech hf. | osteoporosis, skeletal-related events in advanced malignancies | phase_1 | — | $67M |
| 2023 | COYA 302 | Coya Therapeutics, Inc. | amyotrophic lateral sclerosis | preclinical | $8M | $733M |
| 2023 | COYA 302 | Coya Therapeutics, Inc. | amyotrophic lateral sclerosis | preclinical | $8M | $733M |
| 2023 | COYA 302 | Coya Therapeutics | ALS | preclinical | $8M | $725M |
| 2023 | COYA 302 | Coya Therapeutics, Inc. | neurodegenerative diseases | preclinical | $8M | $725M |
| 2023 | toripalimab | Shanghai Junshi Biosciences Co., Ltd. | solid_tumor | approved | $7M | $728M |
How this is computed
For each Dr. Reddy's Laboratories SA deal we find the median total deal value of comparable transactions (same therapeutic area + phase, falling back to TA-only with ≥3 peers). The buyer’s deal divided by the peer median is the per-deal premium. We trim outliers, take the trimmed mean, and clamp to [0.7×, 1.5×] to reject data errors. Confidence scales with sample size.
Trimmed mean of 5 disclosed deal premiums vs. peer medians. Raw premium 0.328, clamped to [0.7, 1.5].